The deal, worth up to $5.2 billion, highlights CEO Mike Doustdars efforts to fend off competition from Eli Lilly. Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmakers new CEO to boost growth.
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Fast Company - 9 Oct 2025 14:19
The deal, worth up to $5.2 billion, highlights CEO Mike Doustdars efforts to fend off competition from Eli Lilly. Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmakers new CEO to boost growth.
Share this Article
Recommended